Video

Dr. Essel on Quantitative Computed Tomography Image Feature Analysis in Gynecologic Cancers

Kathleen G. Essel, MD, gynecologic oncology fellow at the University of Oklahoma Health Science Center with the Stephenson Cancer Center, discusses the benefits of using quantitative computed tomography image feature analysis to predict response to immune checkpoint inhibitors in patients with gynecologic cancers.

Kathleen G. Essel, MD, fellow at the University of Oklahoma Health Science Center with the Stephenson Cancer Center, discusses the benefits of using quantitative computed tomography (CT) image feature analysis to predict response to immune checkpoint inhibitors in patients with gynecologic cancers.

In a recent trial, Essel and colleagues set out to prove the hypothesis that quantitative image feature analysis computed from CT images prior to and following the start of therapy with an immune checkpoint inhibitor would better predict patient response to treatment than conventional RECIST and immune RECIST criteria and they were successful. The analysis was found to accurately predict response to these inhibitors in patients with recurrent gynecologic cancer.

Essel says that not only is it a very useful tool, it is a cost-effective one compared with other imaging tools that have been explored, such as MRIs or PET CTs, which are also very hard to access in rural areas without many academic health centers. CTs are much more universal, she adds; they’re a quick, viable option that will help providers figure out whether a patient is responsive to treatment. Prospective clinical trials incorporating this tool into immunotherapy studies are needed, Essel concludes.

View more from the 2019 SGO Winter Meeting

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center